Latest From Kyverna Therapeutics
Recent venture funding for emerging biopharma companies, including CF PharmTech, Codagenix, Empirico, Epirium, Generation, Kyverna, NorthSea, VectivBio, Rig and Tarsus.
Private Company Edition: VC deals fell short of the record-breaking level seen in 2018 and financings may slow a bit more in 2020. Also, UPMC and Frazier close new VC funds, and Emendo raises $61m for gene-editing platform.
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
- Gene Therapy, Cell Therapy
- Therapeutic Areas
- Immune Disorders
- North America
- Company Type
- Parent & Subsidiaries
- Kyverna Therapeutics
- Senior Management
Dominic Borie, MD, PhD, CEO
Jeffrey Greve, PhD, CSO
Ryan Jones, Head, Bus. Operations
- Contact Info
740 Heinz Ave.
Berkeley, CA 94710
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.